PRP for Sports Injuries: Tendon and Muscle Treatment 2026

Why Does PRP Work in Sports Injuries? Biological Mechanism

Musculoskeletal structures such as tendons, ligaments and cartilage have significantly poorer blood supply than muscle tissue; this severely limits the spontaneous healing of damage. In chronic tendinopathy and ligament injuries, the natural repair cascade does not initiate or complete; a "degenerate" tissue forms.

PRP injects a large amount of growth factors into this weak biological environment, restarting the damaged tissue's "forgotten repair cascade":

• PDGF: Stimulates tendon fibroblasts (tenocytes); synthesis of new collagen (type I) is triggered
• VEGF: New capillary vessel formation (angiogenesis); renews the oxygen and nutrient supply to the tendon
• TGF-β: Regulates collagen organisation and matrix remodelling; converts "random" collagen deposition (scar) into "organised" fibres
• IGF-1: Supports the proliferation and survival of muscle and connective tissue cells
• EGF: Stimulates fibrous tissue stem cells; tendon stem/progenitor cell activation

In the 2020 Cochrane update review (Chen et al.), PRP was found to provide significant clinical superiority over placebo and corticosteroid in lateral epicondylitis, plantar fasciitis and partial rotator cuff tears.

Main Indications for PRP in Sports Injuries

PRP does not show equal efficacy in all musculoskeletal injuries. The distinction between high-evidence indications and applications under investigation is important:

Indication	Evidence Level	PRP Type	Expected Benefit
Lateral epicondylitis (Tennis Elbow)	High (Level I–II)	L-PRP or P-PRP	60–75% pain reduction; functional improvement
Plantar fasciitis	High (Level I)	P-PRP or L-PRP	Significant reduction in VAS score; increased walking capacity
Achilles tendinopathy (chronic)	Moderate–high (Level II)	L-PRP	Tendon thickness decreases on ultrasound; pain and stiffness regress
Knee osteoarthritis (Grade I–III)	High (Level I)	P-PRP (intra-articular)	WOMAC score improvement; superior to hyaluronate
Rotator cuff partial tear	Moderate (Level II)	P-PRP or L-PRP	Pain reduction; shoulder function improvement
Muscle injury (Grade I–II)	Moderate (Level II)	L-PRP	Shortened return-to-sport time
ACL surgery post-op	Under investigation (Level III)	P-PRP	Graft maturation may be accelerated; evidence debated

Tennis Elbow (Lateral Epicondylitis): PRP's Strongest Indication

Lateral epicondylitis is a chronic tendinopathy developing at the insertion point of the common extensor tendon (especially ECRB — Extensor Carpi Radialis Brevis) on the lateral epicondyle. It is common in athletes and occupational groups performing repetitive wrist movements. Clinical presentation: pain on load at the outer elbow, reduced grip strength, acute and chronic phases.

Although corticosteroid injection appears effective short-term, it is known to accelerate tendon degeneration long-term. Advantages of PRP in this condition:

• In the 2013 landmark RCT (Mishra et al., Am J Sports Med), PRP provided 71% better pain reduction (VAS) compared to corticosteroid at 6 months; late-phase deterioration was observed in the corticosteroid group
• Re-synthesis of degenerative tendon collagen tissue via PDGF and TGF-β
• Preserves or improves tendon tissue quality, unlike corticosteroids
• Increased peritendinous vascularisation with VEGF; breaks the "avascular tendinopathy" cycle

Application: 2–3 ml PRP injection to the ECRB tendon insertion point under ultrasound (USG) guidance. Procedure duration: 15 minutes. Post-procedure 24–48 hours rest; then gradual stretching exercises begin.

PRP in Achilles Tendinopathy: Biological Response to Chronic Pain

Achilles tendinopathy is particularly common in long-distance runners, athletes and football players; it can be resistant to conservative treatment. The term "tendinitis" is misleading because histological examinations show degenerative changes (tendinosis) rather than inflammation; hence anti-inflammatories have limited effect.

Mechanisms of action of PRP in Achilles tendinosis:

• Tenocyte (tendon fibroblast) proliferation and new type I collagen synthesis (PDGF effect)
• Increased turnover of degenerative tendon matrix (TGF-β)
• Reduction of hypoechoic (degenerative) areas within the tendon visible on ultrasound
• Breaking the "intratendinous hypoxia" cycle with peritendinous new vessel formation

In a 2022 meta-analysis (Filardo et al., Orthop J Sports Med; 14 RCTs), PRP injection in Achilles tendinopathy showed statistically significant VISA-A score superiority over physiotherapy at 3 and 6 months. Mean tendon thickness on ultrasound decreased by 22% at 12 months.

Application: Peritendinous and intratendinous injection under USG guidance, 3–5 ml PRP. Fenestration (multiple needle movements within the tendon) ensures the lesion area is filled with PRP. Post-procedure 48–72 hours rest; then eccentric exercise programme begins.

PRP in Plantar Fasciitis Treatment: Effective Solution for Heel Pain

Plantar fasciitis is a degenerative tendinopathy developing at the insertion point of the plantar fascia on the heel bone (calcaneus); morning first-step heel pain is the characteristic symptom. It is common in athletes and people who stand for long periods.

Typical prerequisite for PRP treatment indication: at least 3–6 months without response to conservative treatment (stretching exercises, orthotics, NSAIDs, physiotherapy). PRP is a strong option in patients meeting these criteria.

In a 2022 systematic review and meta-analysis (Nalluri et al., AOFAS), PRP provided significantly superior VAS and FFI (Foot Function Index) scores compared to corticosteroid at 3 and 6 months. Based on evidence that corticosteroids increase the risk of plantar fascia rupture and are inadequate long-term, PRP's trend towards becoming first-line choice is strengthening in orthopaedic literature.

Application: 3–5 ml PRP injection to the calcaneus insertion area under USG guidance. Procedure: 10–15 minutes. Then 48 hours avoiding heel loading; continued with appropriate orthotics.

Knee Osteoarthritis (Gonarthritis) and Intra-Articular PRP

Knee osteoarthritis is one of the most common musculoskeletal diseases worldwide. Intra-articular PRP injection in Grade I–III osteoarthritis has become a strong option for both pain control and cartilage protection.

Mechanisms of PRP in osteoarthritis:

• Cartilage protection: IGF-1 and TGF-β inhibit chondrocyte (cartilage cell) apoptosis; suppress the cartilage-degrading activity of matrix metalloproteinases (MMP)
• Synovial environment improvement: Anti-inflammatory cytokines reduce IL-1β and TNF-α levels; improve synovial fluid quality
• Endogenous hyaluronic acid synthesis: PRP increases HA synthesis in synoviocytes; intra-articular lubrication improves

In a 2021 meta-analysis (Migliorini et al., Arthroscopy; 25 RCTs, n=2,193), intra-articular PRP showed statistically significant superiority over hyaluronic acid (HA) injection in WOMAC Total and VAS pain scores at 6 months; the difference was most pronounced in Grade II osteoarthritis.

Application: 4–6 ml P-PRP injection into the joint via suprapatellar approach under USG or fluoroscopy guidance. Pure PRP (P-PRP, leucocyte-depleted) is preferred for intra-articular applications; leucocyte-containing formulations carry inflammation potential.

Rotator Cuff Tendinopathy and Shoulder PRP

The rotator cuff is the common tendon of the four muscles (SITS: supraspinatus, infraspinatus, teres minor, subscapularis) providing shoulder stability and rotation movement. Partial tears and chronic tendinopathy are common in athletes and active individuals over 40.

The role of PRP treatment in rotator cuff tendinopathy:

• Tissue preparation with PRP before surgery for partial tears; risk of progression to full tear is reduced
• PRP is a valid option when conservative approach fails in chronic painful tendinopathy
• Accelerating tendon-bone junction (enthesis) healing with PRP after surgery
• Intratendinous injection under USG or MRI guidance; marked superiority over blind injection

Application: 3–4 ml PRP to the supraspinatus tendon lesion under USG guidance. It is known that shoulder PRP injections performed without image guidance "miss" in up to 30% of cases; therefore USG or fluoroscopy is mandatory.

PRP in Muscle Injuries: Grade I and II Muscle Damage

Muscle injury is common especially in football, rugby and athletics; frequently seen in hamstring, quadriceps and gastrocnemius muscles. The role of PRP treatment in muscle injuries is more debated compared to tendon indications; however, there is potential to shorten return-to-sport time in certain indications.

• Grade I (strain) and Grade II (partial tear): PRP injection within the first 48–72 hours may short-circuit the "vicious cycle" (fibrotic scar formation); encourages muscle fibre regeneration
• In the 2010 Radice et al. study (Am J Sports Med), PRP application in Grade II hamstring injury reduced mean return-to-sport time from 37 to 27 days (27% reduction)
• Grade III (complete tear): Surgery is the priority; PRP is considered only as surgical support or post-op recovery acceleration

Application: 3–5 ml L-PRP (leucocyte-containing — preferred in muscle tissue for antimicrobial and regenerative effect) under USG guidance at the injury site. Post-procedure 48 hours rest; then gradual loading protocol.

USG-Guided PRP: Why Is Image Guidance Mandatory?

Ultrasonography (USG) guidance for musculoskeletal PRP applications has now become the gold standard. The accuracy rate of blind (landmark-based) injections is limited to 50–70% depending on the region; this rate shows dramatic variation by target:

Region	Blind Injection Accuracy	Accuracy with USG Guidance
Knee intra-articular	70–78%	99%
Shoulder (subacromial)	65–70%	97%
Lateral epicondylitis	50–60%	98%
Achilles tendon (intratendinous)	55–65%	98%

At Virtuana Clinic (Izmit/Kocaeli), all orthopaedic PRP applications use real-time USG guidance. This approach ensures both that the injection hits the target precisely and prevents vascular or nerve damage.

Superiority of PRP over Corticosteroid

Corticosteroid injection was used for many years as the first choice in chronic tendinopathy and joint pain. However, growing evidence is questioning the long-term efficacy of corticosteroids:

Criterion	Corticosteroid	PRP
Pain reduction at 4–6 weeks	Rapid and marked (70–80%)	Slower onset (40–50%)
Pain reduction at 6 months	Deterioration / relapse common	Continuing improvement (60–75%)
Function score at 1 year	Return to baseline or worse	Significant superiority
Effect on tendon tissue	Tendon degeneration, increased rupture risk	Tendon tissue quality improves
Repeat injection safety	Limited to 2–3 per year (local tissue damage)	3–6 sessions per year safe
Systemic side effects	Glucose elevation, adrenal suppression risk	Minimal (autologous)

Post-Procedure Rehabilitation Protocol

After PRP injection, the rehabilitation programme is critically important to support the tissue healing cascade. Incorrect or premature loading can completely negate the effect of PRP:

• First 48–72 hours (Protection Phase): Rest the injection site; cold compresses are contraindicated (weakens PRP's mechanism of action); avoid NSAIDs (inhibit platelet activity)
• Days 3–14 (Mobilisation Phase): Gradual passive joint movement; avoid heavy loading; active movement within pain limits
• Weeks 2–6 (Progressive Loading Phase): Eccentric strengthening exercises; eccentric protocol is essential especially for tendinopathy patients
• Week 6 – Month 3 (Functional Phase): Sport-specific training; gradual loading increase; physiotherapist supervision recommended

Important note: Avoid NSAIDs (ibuprofen, naproxen) for at least 2 weeks after the procedure. These medications inhibit PRP's platelet-derived cascade and undermine the foundation of treatment. Paracetamol can be safely used for pain management.

PRP in Sports Injuries: Number of Sessions and Treatment Schedule

Orthopaedic PRP protocols vary according to indication and disease severity:

Indication	Sessions	Interval	First Noticeable Response
Lateral epicondylitis	1–3	4–6 weeks	4–8 weeks
Plantar fasciitis	1–3	4–6 weeks	4–6 weeks
Achilles tendinopathy	2–3	4–6 weeks	6–8 weeks
Knee osteoarthritis	3	2–4 weeks	6–8 weeks
Rotator cuff tendinopathy	2–3	4–6 weeks	6–10 weeks
Muscle injury (Grade II)	1–2	2–3 weeks	2–4 weeks

Who Is Not Suitable for This Treatment?

Both general and specific contraindications should be assessed for orthopaedic PRP applications:

• Active cancer or haematological malignancy (growth factors may accelerate tumour progression)
• Thrombocytopaenia (<100,000/μL) — insufficient growth factor production
• Active infection or cellulitis at the injection site
• Anticoagulant therapy (warfarin, NOAC) — haematology/cardiology consultation required beforehand
• Full-thickness tendon rupture — surgical repair is the priority; PRP may be added as support
• Grade IV osteoarthritis (bone-on-bone contact) — arthroplasty (prosthesis) assessment required
• Those using NSAIDs or corticosteroids — medication cessation protocol must be applied before the procedure

Virtuana Clinic Orthopaedic PRP Services

Virtuana Clinic, serving in Kocaeli/Izmit, applies PRP treatments for sports injuries and musculoskeletal problems according to current international protocols and under ultrasonographic guidance. For each patient, a preliminary orthopaedic assessment, imaging examination (USG or MRI where required) and an individualised treatment plan are prepared. Post-procedure physiotherapy programme ensures the therapeutic process is managed comprehensively.

This article is for informational purposes only. Please consult a qualified physician for treatment decisions.